Latest from Wistar Institute

The L'Oreal Paris USA-MRA Team Science Award for Women in Scientific Research grant for $900,000 is focused on understanding and treating metastatic melanoma.
Global collaboration applies Wistar expertise to promising Cormorant therapeutic drug development.
The Wistar Institute is pleased to welcome Cavan Redmond to its Board of Trustees.
Ashani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ß-catenin signaling in melanoma.
Inhibiting EZH2 may improve outcomes in patients with clear cell ovarian carcinoma who harbor a ARID1A mutation.
A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.
The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.
In more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.
Publication Bottom Border
Border Publication